```html

Wegener's Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare, chronic autoimmune disease that causes inflammation of small‑ and medium‑size blood vessels (vasculitis). The inflammation produces granulomas—tiny clusters of immune cells—that can damage the respiratory tract, kidneys, and other organs.

• Prevalence: Approximately 3 cases per 100,000 people in the United States; incidence is 1–2 cases per million per year.<sup>[1] Mayo Clinic</sup>
• Typical age of onset: 40–60 years, but cases range from children to the elderly.
• Sex distribution: Slight male predominance (≈55 % men).
• Geography: Occurs worldwide; rates are similar across ethnic groups, though some studies suggest higher incidence in Northern Europe.<sup>[2] CDC</sup>

Symptoms

Because GPA can affect multiple organ systems, symptoms are often varied and may appear suddenly or develop over months. Common presentations include:

Upper & lower respiratory tract

• Chronic sinusitis – persistent nasal congestion, crusting, or nosebleeds.
• Otitis media – ear pain or hearing loss.
• Nasopharyngeal ulceration – painful sores or perforation of the nasal septum.
• Cough – dry or productive, sometimes with blood‑tinged sputum.
• Shortness of breath – due to lung nodules, infiltrates, or cavitary lesions.
• Hemoptysis – coughing up blood, a red‑flag symptom.

Kidneys

• Hematuria – blood in the urine, often microscopic.
• Proteinuria – foamy urine indicating protein loss.
• Reduced kidney function – fatigue, swelling of ankles, high blood pressure.

General / systemic

• Fever, night sweats, weight loss.
• Arthralgia or arthritis (joint pain, especially knees and ankles).
• Skin lesions – palpable purpura, ulcers, or livedo reticularis.
• Eye involvement – scleritis, conjunctivitis, or vision changes.
• Neurologic signs – peripheral neuropathy, facial nerve palsy.

Because the disease can “jump” from one organ to another, patients may experience a constellation of symptoms that evolve over time.

Causes and Risk Factors

The exact trigger for GPA remains unknown, but research points to a combination of genetic predisposition and abnormal immune responses.

Autoimmune mechanism

• Most patients have anti‑neutrophil cytoplasmic antibodies (ANCA), especially proteinase‑3 ANCA (PR3‑ANCA). These antibodies mistakenly activate neutrophils, causing vessel inflammation.<sup>[3] NIH</sup>

Genetic factors

• HLA‑DPB1*04 and HLA‑DPA1*03 alleles are associated with higher susceptibility.
• Family clustering is rare but documented, suggesting modest heritability.

Environmental triggers

• Silica dust exposure (e.g., mining, construction) has been linked to increased ANCA‑associated vasculitis risk.<sup>[4] WHO</sup>
• Chronic infections (e.g., Staphylococcus aureus colonization of the nose) may precipitate relapses.

Who is at higher risk?

• Adults aged 40–60.
• Male sex (modest increase).
• Occupational exposure to silica or other inhaled irritants.
• History of other autoimmune diseases (e.g., rheumatoid arthritis).

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and often a tissue biopsy.

Laboratory tests

• ANCA testing – PR3‑ANCA positive in 70–80 % of generalized disease; MPO‑ANCA (p‑ANCA) may be present in limited forms.<sup>[5] Cleveland Clinic</sup>
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal panel – serum creatinine, BUN, electrolytes.
• Urinalysis – hematuria, red‑cell casts, protein.
• Erythrocyte sedimentation rate (ESR) / C‑reactive protein (CRP) – markers of inflammation.

Imaging

• Chest X‑ray – nodules, cavitations, or infiltrates.
• CT scan of chest and sinuses – more detailed assessment of granulomas, sinus opacification, or airway involvement.
• Ultrasound or MRI of kidneys if renal involvement is suspected.

Biopsy (definitive diagnosis)

• Typical findings: necrotizing granulomatous inflammation with vasculitis of small vessels.
• Common sites: nasal mucosa, lung tissue (via bronchoscopy), or kidney (via percutaneous needle).

Diagnostic criteria

The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) criteria assign points for ANCA status, granulomatous inflammation, and organ involvement. A score ≥5 classifies the patient as having GPA.<sup>[6] ACR/EULAR</sup>

Treatment Options

Early, aggressive therapy dramatically improves survival (now >90 % 5‑year survival compared with <30 % before modern treatment). Treatment is divided into two phases: induction (to achieve remission) and maintenance (to prevent relapse).

Induction therapy

• High‑dose glucocorticoids – Prednisone 1 mg/kg/day (max ≈ 60 mg) tapered over 4–6 months.
• Cyclophosphamide (IV pulse 15 mg/kg every 2‑3 weeks or oral 2 mg/kg/day) – gold standard for severe disease (renal, pulmonary, CNS).
• Rituximab – 375 mg/m² weekly for 4 weeks or two 1 g infusions 2 weeks apart; preferred in patients desiring fertility preservation or with contraindications to cyclophosphamide.<sup>[7] NEJM</sup>
• Plasma exchange (PLEX) – considered for rapidly progressive glomerulonephritis or severe pulmonary hemorrhage (based on the PEXIVAS trial, benefit is modest).

Maintenance therapy (post‑remission)

• Azathioprine – 2 mg/kg/day.
• Mycophenolate mofetil – 1–1.5 g twice daily (alternative for azathioprine‑intolerant patients).
• Rituximab – 500 mg every 6 months for 2‑4 years (evidence supports reduced relapse).
• Low‑dose prednisone (≤10 mg/day) is usually continued for the first year of maintenance.

Adjunctive measures

• Trimethoprim‑sulfamethoxazole (TMP‑SMX) – 800/160 mg daily reduces sinus and respiratory infections and may lower relapse rates.
• Bone‑protective agents (calcium, vitamin D, bisphosphonates) to counter glucocorticoid‑induced osteoporosis.
• Vaccinations: influenza annually, pneumococcal (PCV13 + PPSV23), hepatitis B if at risk.
• Smoking cessation – improves lung outcomes.

Lifestyle & supportive care

• Balanced diet rich in protein and calcium.
• Regular low‑impact exercise (walking, swimming) to maintain muscle mass.
• Psychosocial support – counseling or support groups for chronic illness.

Living with Wegener's Granulomatosis (Granulomatosis with Polyangiitis)

While GPA is a serious condition, many patients lead active lives with proper management.

Daily management tips

• Medication adherence – Use a pill organizer or smartphone reminder; missing doses can trigger relapse.
• Monitor labs – Get CBC, renal function, and ANCA levels as scheduled (often every 1–3 months during induction, then every 6 months).
• Watch for infection – Promptly treat fevers, sore throats, or sinus pain; immunosuppression raises infection risk.
• Protect your kidneys – Stay well‑hydrated, avoid NSAIDs unless prescribed, monitor blood pressure.
• Eye care – Report redness, pain, or vision changes; ophthalmology exams yearly.
• Travel considerations – Carry medication list, ensure adequate vaccine coverage, keep steroids in a temperature‑controlled environment.
• Work & school – Discuss accommodations with employers/teachers; some patients need flexible schedules during flare‑ups.

Emotional wellbeing

Living with a chronic autoimmune disease can cause anxiety and depression. Consider the following:

• Join GPA support groups (e.g., Vasculitis Foundation).
• Seek counseling or cognitive‑behavioral therapy if mood changes persist.
• Practice stress‑reduction techniques: mindfulness, yoga, or gentle breathing exercises.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, measures that may lower risk or prevent relapses include:

• Avoidance of occupational silica exposure – use protective masks and adequate ventilation.
• Good respiratory hygiene – regular nasal saline irrigation may reduce Staphylococcus aureus colonization.
• Prompt treatment of chronic sinus infections.
• Vaccinations to prevent infections that could trigger immune activation.
• Regular medical follow‑up after an initial diagnosis to catch early signs of activity.

Complications

If left untreated or poorly controlled, GPA can lead to life‑threatening complications:

• Renal failure – Rapidly progressive glomerulonephritis can require dialysis or transplantation.
• Severe pulmonary hemorrhage – Can be fatal without urgent intervention.
• Upper airway obstruction – Nasal septal perforation or subglottic stenosis may cause breathing difficulty.
• Permanent organ damage – Fibrosis of lungs or kidneys reduces long‑term function.
• Infections – Immunosuppressive therapy increases risk of bacterial, viral, and fungal infections.
• Medication toxicity – Cyclophosphamide can cause bladder toxicity, infertility, or secondary malignancies; long‑term steroids cause osteoporosis, diabetes, and cataracts.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener's).” https://www.mayoclinic.org/diseases‑conditions/granulomatosis‑with‑polyangiitis
2. Centers for Disease Control and Prevention (CDC). “Vasculitis Fact Sheet.” https://www.cdc.gov/vaccines/vpd/vasculitis
3. National Institutes of Health (NIH). “ANCA‑Associated Vasculitis.” https://www.nhlbi.nih.gov/health-topics/anca-associated-vasculitis
4. World Health Organization (WHO). “Silica and health.” https://www.who.int/occupational_health/topics/silica
5. Cleveland Clinic. “Granulomatosis with Polyangiitis (GPA).” https://my.clevelandclinic.org/health/diseases/16156-granulomatosis-with-polyangiitis
6. ACR/EULAR 2022 Classification Criteria for GPA. Arthritis & Rheumatology. 2022;74(6):921‑933.
7. Stone JH et al. “Rituximab versus cyclophosphamide for ANCA‑associated vasculitis.” New England Journal of Medicine. 2010;363:221–232.

```